Preferred Label : Anti-TIGIT Bispecific Antibody BMS-986442;
NCIt synonyms : TIGIT Inhibitor BMS-986442; Anti-TIGIT Bispecific Antibody AGEN1777;
NCIt definition : A Fc-enhanced bispecific antibody directed against both the co-inhibitory molecule
and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and
immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and an as of
yet undisclosed receptor expressed specifically on T-cells and natural killer (NK)
cells, with potential immune checkpoint inhibitory, immunomodulating and antineoplastic
activities. Upon administration, the anti-TIGIT bispecific antibody BMS-986442 simultaneously
targets and binds to TIGIT and the undisclosed receptor. Upon binding to TIGIT expressed
on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), BMS-986442
blocks the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor
related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5;
NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor
CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such
as NK cells and CD8 T-cells. This leads to CD226 dimerization and CD226-mediated
signaling and activates the immune system to exert a T-cell-mediated immune response
against cancer cells. In addition, binding of BMS-986442 to the undisclosed target
expressed on T-cells and NK cells may further enhance anti-tumor immune responses.
TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays
a key role in the suppression of T-cell proliferation and activation; it is involved
in tumor cell immune evasion, and the inhibition of antiviral immune responses.;
Molecule name : AGEN 1777; AGEN-1777; BMS-986442; BMS 986442;
NCI Metathesaurus CUI : CL1771395;
Origin ID : C183161;
UMLS CUI : C5783444;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
